Open AccessSyk-Targeted, a New 3-Arylbenzofuran Derivative EAPP-2 Blocks Airway Inflammation of Asthma–COPD Overlap in vivo and in vitro
Author(s) -
Shuyi Li,
Hui Yang,
Jing Yuan,
Ziqian Zhang,
Xuyu Li,
Nan Fang,
Mingbao Lin,
Qi Hou
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s310875
Subject(s) - syk , in vivo , copd , inflammation , in vitro , medicine , asthma , immunology , lyn , pharmacology , cancer research , chemistry , biology , receptor , tyrosine kinase , biochemistry , microbiology and biotechnology
Asthma-chronic obstructive pulmonary (COPD) overlap (ACO) coexists with asthma and COPD syndrome characteristics, with more frequent exacerbations, heavier disease burden, higher medical utilization, and even lower quality of life. However, the ACO standard medications supported by evidence-based medicine have not yet appeared.